Navigation Links
UNC study suggests new approach to common cause of blindness
Date:6/14/2009

CHAPEL HILL, N.C. Researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have identified a new target for the diagnosis and treatment of age-related macular degeneration, the most common cause of blindness in older Americans.

In a study published online June 14, 2009 by the journal Nature, the researchers demonstrate that blocking the activity of a specific protein called CCR3 -- can reduce the abnormal blood vessel growth that leads to macular degeneration. Furthermore, targeting this new protein may prove to be safer and more effective than the current treatment for the disease, which is directed at a protein called vascular endothelial growth factor or "VEGF."

The discovery -- made in mouse models and cultured human cells --may also enable physicians to catch the disease in its earliest stages, before blood vessels have fully infiltrated and destroyed the central portion of the eye's retina -- an area known as the macula -- to cause vision loss.

"It would be much better to prevent the disease in the first place," said study co-author and principal investigator of the UNC study site, Mary Elizabeth Hartnett, M.D., a professor of ophthalmology in the UNC School of Medicine. "An exciting implication of this study was that the CCR3 protein could be detected in early abnormal blood vessel growth, giving us the opportunity to prevent structural damage to the retina and preserve vision."

Age-related macular degeneration (AMD) affects 30 to 50 million people globally, and that number is expected to double in the next decade as the baby boomer generation ages. The disease is currently treated with drugs that block the effects of VEGF, a growth factor that promotes the growth of abnormal blood vessels. However, because this factor is also involved in the growth and health of normal blood vessels, concerns have been raised about the safety of its long-term use. To date, however, these anti-VEGF agents have been found to be safe.

Thus, the investigators sought to identify a new target for treatment that is specific to AMD. They detected the presence of the CCR3 protein in eye tissue from humans with AMD but not in that of individuals of similar age who did not have the disease. When they blocked CCR3, either with drugs or through genetic engineering, they saw a decrease in the generation of abnormal blood vessels. Drugs targeting CCR3 were significantly more effective than those targeting VEGF, meaning this could represent a new therapy for the two-thirds of patients that do not respond to current treatment.

The researchers now may look to see if levels of the protein can be detected in the bloodstream in order to identify people who are at risk of developing the disease. They also plan to search for genetic changes in the CCR3 gene in patients with AMD to better understand its causes.


'/>"/>

Contact: Les Lang
llang@unch.unc.edu
919-966-9366
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... (PRWEB) , ... February 21, 2017 , ... Nancy ... offering readers a way to “ Getting Over the Bump in the Road ” ... and lessons learned on how to cope with the ups and downs experienced by ...
(Date:2/20/2017)... ... February 20, 2017 , ... Silverado today is pleased ... open and operate a state-of-the-art memory care community in Alexandria, Virginia. The new community ... site just outside of Old Town. , The three-story community with underground parking ...
(Date:2/20/2017)... FL (PRWEB) , ... February 20, 2017 , ... ... beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative software ... solution for increasing patient engagement and optimizing care journey management for home healthcare. ...
(Date:2/20/2017)... ... , ... Clearwave is the leading provider in ... XT-series of touch screen terminals. Both companies will be showcasing their solutions at ... provider Posiflex is helping to bridge the gap between healthcare hardware and software ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... Document Router (BDR), the first IoT device from Biscom designed to deliver confidential ... will debut BDR at HIMSS17 and will be conducting demonstrations at ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017   MedPlast, Inc. ... device industry, announced today that it has signed ... Device Manufacturing Services business.   The acquisition broadens ... as a leading services provider to the world,s ... will further expand the company,s capabilities in assembly ...
(Date:2/20/2017)... Provides understanding and access to the ... by the worlds leading healthcare companies. Download ... The Global Renal Failure Partnering Terms and Agreements ... partnering deals and agreements entered into by the ... in partnering deals - Top deals by ...
(Date:2/20/2017)... NEW YORK , Feb. 20, 2017 ... imaging technique that creates detailed images of the organs ... a magnetic field and radio waves. The technique does ... the study of brain function or growth of cancer. ... such as neurology, cardiology, oncology, musculoskeletal, and orthopedics. Hence, ...
Breaking Medicine Technology: